Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

October 25, 2019

Study Completion Date

January 29, 2020

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Damoctocog-alfa-pegol (BAY94-9027, Jivi)

Single dose, 50 IU/kg BAY94-9027 (IU: international Units)

BIOLOGICAL

Rurioctocog alfa pegol (Adynovi)

Single dose, 50 IU/kg Adynovi

Trial Locations (1)

SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia